Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep748 | Pituitary - Clinical | ECE2017

Learning from adult growth hormone deficient patients’ advisory panel

Hey-Hadavi Judith , Camacho-Hubner Cecilia , Kelepouris Nicky

Introduction: Adult Growth Hormone Deficient (AGHD) patients have often a difficult path from diagnosis to treatment. A patient advisory panel was conducted to better understand the AGHD patient journey and how this could be supported. This format was chosen to allow for direct patient to patient interactions and discussions and for physicians to learn.Findings: A total of nine patient advisors (three childhood-onset; six adult-onset, age 33–67 year...

ea0056p617 | Pituitary - Clinical | ECE2018

Living with acromegaly: patient journey in europe vs USA

Hey-Hadavi Judith , vanderLans Joli , Cannito Maria , Kelepouris Nicky

Introduction: Patients with acromegaly have often a challenging path from diagnosis to treatment start and to long-term care. Two separate acromegaly patient advisory panels (one in Europe and one in USA) were conducted with the aim to better learn about their experience and how this could be improved. This format was chosen to allow direct patient to patient interactions and to understand possible unmet needs and opportunities within the acromegaly community. An independent m...

ea0073oc13.3 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

Cardiovascular and metabolic safety of growth hormone treatment in adult patients with growth hormone deficiency: real-world data from two large studies in the USA and Europe

Charlotte Höybye , Kelepouris Nicky , Nedjatian Navid

IntroductionEvidence suggests that adults with growth hormone deficiency (AGHD) exhibit metabolic abnormalities that are typical of the metabolic syndrome and are risk factors for type 2 diabetes (T2D). Concerns about undesirable effects of growth hormone replacement therapy (GHRT) on glucose metabolism have been raised, but the risk of T2D from AGHD has mixed evidence. This analysis aims to evaluate cardiovascular (CV) and metabolic safety of GHRT in th...

ea0081ep673 | Pituitary and Neuroendocrinology | ECE2022

Growth hormone (GH) replacement therapy (GHRT) in patients with adult GH deficiency (AGHD) aged ≥60 years: data from NordiNet® IOS and the ANSWER Program

M. Weber Matthias , B. Gordon Murray , Hoybye Charlotte , H. Olsen Anne , Kelepouris Nicky , Nedjatian Navid , M.K. Biller Beverly

Introduction: There are limited data on the effectiveness and safety of GHRT in older patients with AGHD. We compared real-world GHRT outcomes in older (aged ≥60 years) vs middle-aged (35–<60 years) adults.Methods: NordiNet® IOS (NCT00960128) and ANSWER (NCT01009905) were non-interventional studies investigating long-term effectiveness and safety of GHRT with Norditropin® (somatropin, Novo Nordisk). Safety was assessed in the ful...